FDA grants Orphan Drug Designation to Axovant Gene Therapies for AXO-AAV-GM1, its GM1 Gangliosidosis Candidate
Axovant Gene Therapies (NASDAQ: AXGT) announced the grant of an Orphan Drug Designation for AXO-AAV-GM1, the Company’s investigational gene therapy for the treatment of GM1 gangliosidosis. AXO-AAV-GM1 is capable of restoring the β-galactosidase enzyme activity by delivering a functional copy of the dysfunctional GLB1 gene,...
